Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: Insights into the mechanism of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 2, 1999, Pages 886-894

  Kleckner, Nancy W ^a   Glazewski, Jill C ^a   Chen, Chi Chiung ^a   Moscrip, Tammy D ^a  

^a BATES COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCITATORY AMINO ACID RECEPTOR; FELBAMATE; HALOPERIDOL; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; BINDING SITE; CONFERENCE PAPER; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; LENNOX GASTAUT SYNDROME; NEUROTRANSMISSION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTON TRANSPORT; SEIZURE; XENOPUS;

ALGORITHMS; ANIMALS; ANTICONVULSANTS; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GLYCINE; HYDROGEN-ION CONCENTRATION; MEMBRANE POTENTIALS; MUTATION; OOCYTES; PATCH-CLAMP TECHNIQUES; PROPYLENE GLYCOLS; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; XENOPUS LAEVIS;

EID: 0032937917     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Adusumalli VE, Wichmann JK, Kucharczyk N, Kamin M, Sofia DR, French J, Sperling M, Bourgeois B, Devinsky O, Dreifuss FE, Kuzniecky RI, Faught E and Rosenfeld W (1994) Drug concentrations in human brain tissue samples from epileptic patients treated with felbamate. Drug Metab Dispos 22:168-169.
2. Brimecombe JC, Gallagher MJ, Lynch DR and Aizenman E (1998) An NR2B point mutation affecting haloperidol and CP101,606 sensitivity of single recombinant N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 286:627-634.
3. Buller AL, Larson HC, Schneider BE, Beaton JA, Morrisett RA and Monaghan DT (1994) The molecular basis of NMDA receptor subtypes: Native receptor diversity is predicted by subunit composition. J Neurosci 14:5471-5484.
4. Coffin V, Cohen-Williams M and Barnett A (1994) Selective antagonism of the anticonvulsant effects of felbamate by glycine. Eur J Pharmacol 256:R9-R10.
5. Engel J Jr and Pedley TA (1998) Epilepsy: A Comprehensive Textbook. Lippincott-Raven, Philadelphia.
6. Gallagher MJ, Huang H, Grant ER and Lynch DR (1997) The NR2B-specific interactions of polyamines and protons with the N-methyl-D-aspartate receptor. J Biol Chem 272:24971-24979.
7. Gallagher MJ, Huang H and Lynch DR (1998) Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions. J Neurochem 70: 2120-2128.
8. Gallagher MJ, Huang H, Pritchett DB and Lynch DR (1996) Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem 271:9603-9611.
9. Ilyin VI, Whittemore ER, Guastella J, Weber E and Woodward RM (1996) Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol. Mol Pharmacol 50:1541-1550.
10. Kanthasamy AG, Matsumoto RR, Gunasekar PG and Truong DD (1995) Excitoprotective effect of felbamate in cultured cortical neurons. Brain Res 705:97-104.
11. Kawajiri S and Dingledine R (1993) Multiple structural determinants of voltage-dependent magnesium block in recombinant NMDA receptors. Neuropharmacology 32:1203-1211.
12. Kew JNC, Richards JG, Mutel V and Kemp JA (1998) Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons. J Neurosci 18:1935-1943.
13. Kew JNC, Trube G and Kemp JA (1996) A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol 497.3:761-772.
14. Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumanishi T, Arakawa M and Mishina M (1992) Molecular diversity of the NMDA receptor channel. Nature (London) 358:36-41.
15. Laube B (1998) Evidence for a tetrameric structure of recombinant NMDA receptors. J Neurosci 18:2954-2961.
16. Lynch DR and Gallagher MJ (1996) Inhibition of N-methyl-D-aspartate receptors by haloperidol: Developmental and pharmacological characterization in native and recombinant receptors. J Pharmacol Exp Ther 279:154-161.
17. Lynch DR, Lawrence JJ, Lenz S, Anegawa NJ, Dichter M and Pritchett DB (1995) Pharmacological characterization of heterodimeric NMDA receptors composed of NR 1a and 2B subunits: Differences with receptors formed from NR 1a and 2A. J Neurochem 64:1462-1468.
18. McBain CJ and Mayer ML (1994) N-Methyl-D-aspartic acid receptor structure and function. Physiol Rev 74:723-723.
19. 3H]glycine binding in rat brain and sections of human postmortem brain. J Pharmacol Exp Ther 286:999.
20. McCabe RT, Wasterlain CG, Kucharczyk N, Sofia DR and Vogel JR (1993) Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 264:1248-1252.
21. McNamara JO (1994) Cellular and molecular basis of epilepsy. J Neurosci 14:3413-3425.
22. Monyer H, Burnashev N, Laurie DJ, Sakmann B and Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12:529-540.
23. Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, Lomeli H, Burnashev N, Sakmann B and Seeburg PH (1992) Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science (Wash DC) 256:1217-1221.
24. Pahk AJ and Williams K (1997) Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci Lett 225:29-32.
25. Pellock JM and Brodie MJ (1997) Felbamate: 1997 update. Epilepsia 38:1261-1264.
26. Pugliese AM, Passani MB, Pepeu G and Corradetti R (1996) Felbamate decreases synaptic transmission in the CA1 region of rat hippocampal slices. J Pharmacol Exp Ther 279:1100-1108.
27. A receptors. Ann Neurol 35:229-234.
28. Rogawski MA and Porter RJ (1990) Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42:223-270.
29. +-stimulated release of glutamate from mouse cortex. Eur J Pharmacol 315:285-288.
30. Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A and Bernardi G (1996) Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 277:121-127.
31. Subramanian S, Rho JM, Penix L, Donevan SD, Fielding RP and Rogawski MA (1995) Felbamate block of the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther 273:878-886.
32. + channels from human and rat brain. Eur J Pharmacol 316:373-377.
33. 2+ concentration. Eur J Pharmacol Mol Pharmacol 289:229-233.
34. Troupin AS, Montouris G and Hussein G (1997) Felbamate: Therapeutic range and other kinetic information. J Epilepsy 10:26-31.
35. Wallis RA and Panizzon KL (1993) Glycine reversal of felbamate hypoxic protection. Neuroreport 4:951-954.
36. 3H]DCKA-labeled strychnine-insensitive glycine receptors in human postmortem brain. Exp Neurol 129:244-250.
37. White HS, Harmsworth WL, Sofia RD and Wolf HH (1995) Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 20:41-48.
38. White HS, Wolf HH, Swinyard EA, Skeen GA and Sofia RD (1992) A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 33:564-572
39. Williams K (1993) Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: Selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44:851-859.
40. Zhang S, Mott DD, Doherty J and Dingledine R (1997) The ifenprodil analogue CP-101,606 inhibits NMDA receptors by enhancing proton inhibition. Soc Neurosci Abstr 23:945.